Fulgent Genetics, Inc. Common Stock (FLGT) is a publicly traded Healthcare sector company. As of May 21, 2026, FLGT trades at $16.26 with a market cap of $450.15M and a P/E ratio of 0.00. FLGT moved +0.00% today. Year to date, FLGT is -35.32%; over the trailing twelve months it is -22.67%. Its 52-week range spans $13.46 to $31.04. Analyst consensus is buy with an average price target of $18.50. Rallies surfaces FLGT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Fulgent Genetics Reports Q4 Sales Up 9% and Guides $350M 2026 Revenue: Fulgent Genetics posted 2025 revenue of $322.7 million, up 14%, with Q4 sales of $83.3 million (9% rise), a $23.4 million net loss and $5.2 million profit. For 2026, a $59 million customer transition will be offset by $55.5 million Bako/StrataDx deals targeting about $350 million revenue.
| Metric | Value |
|---|---|
| Price | $16.26 |
| Market Cap | $450.15M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $31.04 |
| 52-Week Low | $13.46 |
| Volume | 4.43K |
| Avg Volume | 0 |
| Revenue (TTM) | $320.35M |
| Net Income | $-75.01M |
| Gross Margin | 38.71% |
2 analysts cover FLGT: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $18.50.